Cystic-fibrosis-related diabetes: time for oral drugs?

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 2, 2018, Pages 85-87

  Moran, Antoinette ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; REPAGLINIDE;

ADVERSE OUTCOME; BODY WEIGHT DISORDER; BODY WEIGHT GAIN; CARDIOVASCULAR RISK; CELL STRESS; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; FORCED VITAL CAPACITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LEAN BODY WEIGHT; LIPOLYSIS; LUNG DISEASE; LUNG FUNCTION; MAXIMUM TOLERATED DOSE; MICROANGIOPATHY; MICROVASCULATURE; MORBIDITY; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS ISLET BETA CELL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; THERAPY EFFECT; TREATMENT OUTCOME; UNDERWEIGHT;

CYSTIC FIBROSIS; DIABETES MELLITUS; HUMANS;

EID: 85035344085     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30407-2     Document Type: Note

References (6)

1. Schwarzenberg, SJ, Thomas, W, Olsen, TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 30 (2007), 1056–1061.
2. Moran, A, Becker, D, Casella, SJ, et al. Epidemiology, pathophysiology and prognstic implications of CFRD: a technical review. Diabetes Care 33 (2010), 2677–2683.
3. Moran, A, Brunzell, C, Cohen, RC, et al. Clinical care guidelines for CFRD: recommendations from the Cystic Fibrosis Foundation, the American Diabetes Association and the Pediatric Endocrine Society. Diabetes Care 33 (2010), 2697–2708.
4. Hanas, R, Donaghue, KC, Klingensmith, G, Swift, PG, ISPAD clinical practice consensus guidelines 2009 compendium. Pediatr Diabetes 10:suppl 12 (2009), 1–2.
5. Ballman, M, Hubert, D, Assael, BR, et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6 (2018), 114–121.
6. Moran, A, Pekow, P, Grover, P, et al. Insulin therapy to improve BMI in cystic fibrosis related diabetes without fasting hyperglycemia: results of the Cystic Fibrosis Related Diabetes Therapy trial. Diabetes Care 32 (2009), 1783–1788.